Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Renal Cell 86Kidney Neoplasms 25Neoplasms 24Breast Neoplasms 18Gastrointestinal Stromal Tumors 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Pancreatic Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Solid Tumors 5Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Neuroendocrine Tumors 5Melanoma 5Glioblastoma 5Carcinoma 5Sarcoma 4Liver Neoplasms 4Esophageal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Adenoma, Islet Cell 4Thyroid Cancer, Papillary 3

Interventions

pazopanib 2Sunitinib 2Sorafenib 2verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1Valproic Acid 1Sirolimus 1Interleukin-27 1Hydralazine 1Erlotinib Hydrochloride 1Azurin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Refractory Solid Tumors × Sunitinib × Clear all
NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase 4 Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡